[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Furuichi et al., 2005 - Google Patents

Depletion of CD25+ CD4+ T cells (Tregs) enhances the HBV-specific CD8+ T cell response primed by DNA immunization

Furuichi et al., 2005

View HTML
Document ID
2324770289106228437
Author
Furuichi Y
Tokuyama H
Ueha S
Kurachi M
Moriyasu F
Kakimi K
Publication year
Publication venue
World journal of gastroenterology: WJG

External Links

Snippet

AIM: Persistent hepatitis B virus (HBV) infection is characterized by a weak CD8+ T cell response to HBV. Immunotherapeutic strategies that overcome tolerance and boost these suboptimal responses may facilitate viral clearance in chronically infected individuals …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Similar Documents

Publication Publication Date Title
Furuichi et al. Depletion of CD25+ CD4+ T cells (Tregs) enhances the HBV-specific CD8+ T cell response primed by DNA immunization
Toka et al. CD4+ CD25+ T cells regulate vaccine-generated primary and memory CD8+ T-cell responses against herpes simplex virus type 1
Sammicheli et al. Inflammatory monocytes hinder antiviral B cell responses
Chen et al. Immune tolerance split between hepatitis B virus precore and core proteins
Welten et al. CD27-CD70 costimulation controls T cell immunity during acute and persistent cytomegalovirus infection
Hebeis et al. Activation of virus-specific memory B cells in the absence of T cell help
Marshall et al. Virus-induced transient immune suppression and the inhibition of T cell proliferation by type I interferon
Verma et al. Cytomegalovirus-specific CD4 T cells are cytolytic and mediate vaccine protection
Isogawa et al. Immunobiology of hepatitis B virus infection
Delluc et al. Quantitative analysis of the CD4 T‐cell repertoire specific to therapeutic antibodies in healthy donors
Frelin et al. A mechanism to explain the selection of the hepatitis e antigen-negative mutant during chronic hepatitis B virus infection
Hühr et al. Impaired T‐cell responses in domestic pigs and wild boar upon infection with a highly virulent African swine fever virus strain
Zeng et al. IL-12–based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier
Heslop et al. Adoptive T-cell therapy for Epstein-Barr virus–related lymphomas
Barrett et al. The coming of age of adoptive T-cell therapy for viral infection after stem cell transplantation
Akbar et al. Safety and efficacy of hepatitis B surface antigen-pulsed dendritic cells in human volunteers
Park et al. Primary induction of CD4 T cell responses in nasal associated lymphoid tissue during group A streptococcal infection
Pishraft-Sabet et al. Enhancement of HCV polytope DNA vaccine efficacy by fusion to an N-terminal fragment of heat shock protein gp96
Joh et al. T cell-mediated antitumor immune response eliminates skin tumors induced by mouse papillomavirus, MmuPV1
Quinn et al. Accelerating the secondary immune response by inactivating CD4+ CD25+ T regulatory cells prior to BCG vaccination does not enhance protection against tuberculosis
Nakayama et al. C3 promotes expansion of CD8+ and CD4+ T cells in a Listeria monocytogenes infection
JP2014516538A (en) Regulated immunodominant therapy
Wen Antigen–antibody immunogenic complex: promising novel vaccines for microbial persistent infections
Fang et al. CD4+ CD25+ Foxp3− T-regulatory cells produce both gamma interferon and interleukin-10 during acute severe murine spotted fever rickettsiosis
CN115894708B (en) Human cytomegalovirus epitope chimeric peptide and application thereof